Ketanserin

In the clinical treatment of hypertension complicated with peripheral vascular disease, antihypertensive drugs with multiple action targets have always been the key direction of clinical exploration. Ketanserin is an antihypertensive drug belonging to the class of 5-hydroxytryptamine receptor antagonists. It can selectively block 5-HT2A receptors, and also has mild α1 and H1 receptor antagonistic effects. It can not only reduce peripheral vascular resistance to produce a stable antihypertensive effect, but also improve lower limb microcirculation and reduce the risk of platelet aggregation. It is mainly used clinically for the treatment of various types of hypertension, especially for elderly hypertensive patients with peripheral vascular diseases such as Raynaud's disease and intermittent claudication, and can reduce the risk of thromboembolic complications while lowering blood pressure.

At present, the global ketanserin market scale is relatively stable, and the overall market is in the stage of mature application. In 2023, the global market sales were approximately USD 120 million, and the compound annual growth rate was maintained at around 2.3%. The competitive landscape is dominated by generic drug enterprises. Europe is the main production region of API, accounting for 62% of the global production capacity. The domestic market is still in the introduction stage, with few approved preparation varieties and has not been included in the national centralized procurement catalogue. With the increase of refined demand for the treatment of hypertension comorbidities in China, its clinical application space is expected to be further released. (Note: Dimensions without verifiable time-sensitive market data are not included for the time being)

The original research enterprise of ketanserin is Janssen Pharmaceuticals, with the original brand name Sufrexal. The core compound patent expired globally in 2001. The main dosage form approved by the original research is tablet, with conventional specifications of 20mg and 40mg, and its 20mg tablet has been included in the FDA Reference Listed Drug Catalogue. At present, no ketanserin preparation has been approved for marketing in China, and no publicly available A-status ketanserin API registration number has been found in the CDE API registration database. (Data as of April 2025, please refer to the official CDE website for the latest information)

For relevant enterprises that are carrying out generic drug R&D and quality research of ketanserin, CATO can provide a full set of impurity reference standards for this API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully support the full-process research needs of enterprises from prescription screening to consistency evaluation.